EGFR mutations in lung cancer: From tissue testing to liquid biopsy

Francesca Fenizia; Antonella De Luca; Raffaella Pasquale; Alessandra Sacco; Laura Forgione; Matilde Lambiase; Alessia Iannaccone; Nicoletta Chicchinelli; Renato Franco; Antonio Rossi; Alessandro Morabito; Gaetano Rocco; Maria Carmela Piccirillo; Nicola Normanno

doi:10.2217/fon.15.23

EGFR mutations in lung cancer: From tissue testing to liquid biopsy

Francesca Fenizia, Antonella De Luca, Raffaella Pasquale, Alessandra Sacco, Laura Forgione, Matilde Lambiase, Alessia Iannaccone, Nicoletta Chicchinelli, Renato Franco, Antonio Rossi, Alessandro Morabito, Gaetano Rocco, Maria Carmela Piccirillo, Nicola Normanno

Istituto Nazionale Tumori Fondazione G. Pascale

Research output: Contribution to journal › Article › peer-review

Abstract

The presence of EGFR mutations predicts the sensitivity to EGF receptor (EGFR)-tyrosine kinase inhibitors in a molecularly defined subset of non-small-cell lung carcinoma (NSCLC) patients. For this reason, EGFR testing of NSCLC is required to provide personalized treatment options and better outcomes for NSCLC patients. As surgery specimens are not available in the majority of NSCLC, other currently available DNA sources are small biopsies and cytological samples, providing however limited and low-quality material. In order to address this issue, the use of surrogate sources of DNA, such as blood, serum and plasma samples, which often contains circulating free tumor DNA or circulating tumor cells, is emerging as a new strategy for tumor genotyping.

Original language	English
Pages (from-to)	1611-1623
Number of pages	13
Journal	Future Oncology
Volume	11
Issue number	11
DOIs	https://doi.org/10.2217/fon.15.23
Publication status	Published - Jun 1 2015

Keywords

EGFR mutations
EGFR-TKIs
liquid biopsy
mechanisms of resistance
non-small-cell lung carcinoma
targeted therapy

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.2217/fon.15.23

Fingerprint Dive into the research topics of 'EGFR mutations in lung cancer: From tissue testing to liquid biopsy'. Together they form a unique fingerprint.

Cite this

EGFR mutations in lung cancer : From tissue testing to liquid biopsy. / Fenizia, Francesca; De Luca, Antonella ; Pasquale, Raffaella ; Sacco, Alessandra ; Forgione, Laura; Lambiase, Matilde; Iannaccone, Alessia; Chicchinelli, Nicoletta; Franco, Renato; Rossi, Antonio; Morabito, Alessandro; Rocco, Gaetano; Piccirillo, Maria Carmela ; Normanno, Nicola.

In: Future Oncology, Vol. 11, No. 11, 01.06.2015, p. 1611-1623.

Research output: Contribution to journal › Article › peer-review

Fenizia, Francesca ; De Luca, Antonella ; Pasquale, Raffaella ; Sacco, Alessandra ; Forgione, Laura ; Lambiase, Matilde ; Iannaccone, Alessia ; Chicchinelli, Nicoletta ; Franco, Renato ; Rossi, Antonio ; Morabito, Alessandro ; Rocco, Gaetano ; Piccirillo, Maria Carmela ; Normanno, Nicola. / EGFR mutations in lung cancer : From tissue testing to liquid biopsy. In: Future Oncology. 2015 ; Vol. 11, No. 11. pp. 1611-1623.

@article{319ebc55a0d34a38b5e568d313aabf67,

title = "EGFR mutations in lung cancer: From tissue testing to liquid biopsy",

abstract = "The presence of EGFR mutations predicts the sensitivity to EGF receptor (EGFR)-tyrosine kinase inhibitors in a molecularly defined subset of non-small-cell lung carcinoma (NSCLC) patients. For this reason, EGFR testing of NSCLC is required to provide personalized treatment options and better outcomes for NSCLC patients. As surgery specimens are not available in the majority of NSCLC, other currently available DNA sources are small biopsies and cytological samples, providing however limited and low-quality material. In order to address this issue, the use of surrogate sources of DNA, such as blood, serum and plasma samples, which often contains circulating free tumor DNA or circulating tumor cells, is emerging as a new strategy for tumor genotyping.",

keywords = "EGFR mutations, EGFR-TKIs, liquid biopsy, mechanisms of resistance, non-small-cell lung carcinoma, targeted therapy",

author = "Francesca Fenizia and {De Luca}, Antonella and Raffaella Pasquale and Alessandra Sacco and Laura Forgione and Matilde Lambiase and Alessia Iannaccone and Nicoletta Chicchinelli and Renato Franco and Antonio Rossi and Alessandro Morabito and Gaetano Rocco and Piccirillo, {Maria Carmela} and Nicola Normanno",

year = "2015",

month = jun,

day = "1",

doi = "10.2217/fon.15.23",

language = "English",

volume = "11",

pages = "1611--1623",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "11",

}

TY - JOUR

T1 - EGFR mutations in lung cancer

T2 - From tissue testing to liquid biopsy

AU - Fenizia, Francesca

AU - De Luca, Antonella

AU - Pasquale, Raffaella

AU - Sacco, Alessandra

AU - Forgione, Laura

AU - Lambiase, Matilde

AU - Iannaccone, Alessia

AU - Chicchinelli, Nicoletta

AU - Franco, Renato

AU - Rossi, Antonio

AU - Morabito, Alessandro

AU - Rocco, Gaetano

AU - Piccirillo, Maria Carmela

AU - Normanno, Nicola

PY - 2015/6/1

Y1 - 2015/6/1

N2 - The presence of EGFR mutations predicts the sensitivity to EGF receptor (EGFR)-tyrosine kinase inhibitors in a molecularly defined subset of non-small-cell lung carcinoma (NSCLC) patients. For this reason, EGFR testing of NSCLC is required to provide personalized treatment options and better outcomes for NSCLC patients. As surgery specimens are not available in the majority of NSCLC, other currently available DNA sources are small biopsies and cytological samples, providing however limited and low-quality material. In order to address this issue, the use of surrogate sources of DNA, such as blood, serum and plasma samples, which often contains circulating free tumor DNA or circulating tumor cells, is emerging as a new strategy for tumor genotyping.

AB - The presence of EGFR mutations predicts the sensitivity to EGF receptor (EGFR)-tyrosine kinase inhibitors in a molecularly defined subset of non-small-cell lung carcinoma (NSCLC) patients. For this reason, EGFR testing of NSCLC is required to provide personalized treatment options and better outcomes for NSCLC patients. As surgery specimens are not available in the majority of NSCLC, other currently available DNA sources are small biopsies and cytological samples, providing however limited and low-quality material. In order to address this issue, the use of surrogate sources of DNA, such as blood, serum and plasma samples, which often contains circulating free tumor DNA or circulating tumor cells, is emerging as a new strategy for tumor genotyping.

KW - EGFR mutations

KW - EGFR-TKIs

KW - liquid biopsy

KW - mechanisms of resistance

KW - non-small-cell lung carcinoma

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84930607424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930607424&partnerID=8YFLogxK

U2 - 10.2217/fon.15.23

DO - 10.2217/fon.15.23

M3 - Article

C2 - 26043215

AN - SCOPUS:84930607424

VL - 11

SP - 1611

EP - 1623

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 11

ER -